{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:14:18Z","timestamp":1788779658218,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03341-5","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:02:08Z","timestamp":1728025328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon"],"prefix":"10.1186","volume":"24","author":[{"given":"Ala I.","family":"Sharara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alrazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saniour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine Abou","family":"Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Geagea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Ghoubar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"1","key":"3341_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, Rodriguez C, Barreiro-de Acosta M, Martinez-Cadilla J, et al. Tofacitinib in Ulcerative Colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis. 2021;15(1):35\u201342.","journal-title":"J Crohns Colitis"},{"issue":"18","key":"3341_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"8","key":"3341_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","volume":"19","author":"P Deepak","year":"2021","unstructured":"Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, et al. Safety of Tofacitinib in a real-world cohort of patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021;19(8):1592\u2013601. e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"3341_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, et al. Real-world effectiveness of Tofacitinib for moderate to severe Ulcerative Colitis: a Multicentre UK Experience. J Crohns Colitis. 2020;14(10):1385\u201393.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3341_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","volume":"52","author":"L Lair-Mehiri","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52(3):268\u201373.","journal-title":"Dig Liver Dis"},{"key":"3341_CR6","doi-asserted-by":"publisher","first-page":"175628482110640","DOI":"10.1177\/17562848211064004","volume":"14","author":"LA Lucaciu","year":"2021","unstructured":"Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx L, Jones GR, et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Th Adv Gastroenterol. 2021;14:17562848211064004.","journal-title":"Th Adv Gastroenterol"},{"issue":"10","key":"3341_CR7","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/MEG.0000000000002028","volume":"33","author":"T Straatmijer","year":"2021","unstructured":"Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D\u2019Haens GR, et al. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol. 2021;33(10):1288\u201397.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3341_CR8","doi-asserted-by":"crossref","first-page":"175628481984863","DOI":"10.1177\/1756284819848631","volume":"12","author":"F D\u2019Amico","year":"2019","unstructured":"D\u2019Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Th Adv Gastroenterol. 2019;12:1756284819848631.","journal-title":"Th Adv Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03341-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:03:28Z","timestamp":1728025408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03341-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03341-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was granted by the Institutional Review Board (IRB) of the American University of Beirut (AUB). The need of consent was waived by IRB at AUB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Ala Sharara is an employee at AUBMC which had received funding for the conduct of this study. Marcelle Ghoubar is a full-time Pfizer employee. Other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"349"}}